Biotechnology company Moderna, Inc. (MRNA) announced Monday positive results from a Phase 3 efficacy study evaluating the relative vaccine efficacy (rVE) against influenza illness of mRNA-1010, the Company's seasonal influenza (flu) vaccine candidate, compared to a licensed standard-dose seasonal influenza vaccine in adults aged 50 years and older.
mRNA-1010 demonstrated superior rVE of 26.6% higher than a licensed standard-dose seasonal influenza vaccine in adults aged 50 years and older in the overall study population.
Additionally, strong rVE was observed for each influenza strain contained in the vaccine, including A/H1N1 rVE of 29.6%), A/H3N2 rVE of 22.2%), and the B/Victoria lineages rVE of29.1%.
Subgroup analyses confirmed a consistently strong rVE point estimate across age groups, risk factors and previous influenza vaccination status. In participants aged 65 years and older, mRNA-1010 demonstrated an rVE of 27.4%.
In a previous Phase 3 study, mRNA-1010 had already demonstrated superior seroconversion rates and geometric mean titer ratios (GMR) against all strains included in the vaccine compared to both high-dose and standard-dose licensed seasonal influenza vaccine. The Phase 3 study was a randomized, observer-blind, active-controlled, case-driven, pivotal efficacy, immunogenicity and safety study. The trial enrolled 40,805 adults aged 50 years and older across 11 countries. Participants were randomly assigned to receive either a single dose of mRNA-1010 or a standard-dose licensed comparator, with a median follow-up of six months.
Safety and tolerability of mRNA-1010 were consistent with reported results from a previous Phase 3 study. The CompModerna reports Positive Phase 3 Results for MRNA Seasonal Flu Vaccine Candidate
Moderna, Inc. (MRNA) announced Monday positive results from a Phase 3 efficacy study evaluating the relative vaccine efficacy (rVE) against influenza illness of mRNA-1010, the Company's seasonal influenza (flu) vaccine candidate, compared to a licensed standard-dose seasonal influenza vaccine in adults aged 50 years and older.
Safety and tolerability of mRNA-1010 were consistent with reported results from a previous Phase 3 study. The Company will now engage with regulators on filing submissions for mRNA-1010.
any will now engage with regulators on filing submissions for mRNA-1010.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.